Want to see LYRA full AI Analyst Report?
Top Page
Lyra Therapeutics
(OTC:LYRA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.36
▼(-31.35% Downside)
Action:Reiterated
Date:07/15/26
The score is driven primarily by weak financial performance—minimal/declining revenue, ongoing losses and cash burn, and a balance sheet showing negative equity and elevated leverage—indicating high financing risk. Technicals add pressure with a clear downtrend and negative momentum. Valuation offers limited support due to a negative P/E and no dividend yield data, while the sublease termination event is a modest additional negative for near-term cash flow.
Positive Factors
Proprietary drug-delivery platform
Lyra’s focus on a proprietary, localized long‑acting drug-delivery platform for sinonasal tissues creates a durable technical moat in ENT therapeutics. If clinical programs advance, the platform can enable differentiated safety/efficacy profiles and higher barriers to generic competition over the next 2–6 months and beyond.
Negative Factors
Negative equity and elevated debt
Equity turning negative and material debt relative to assets signals capital erosion and higher financial risk. This condition narrows funding options, increases borrowing costs or dilution risk, and can constrain strategic choices, creating sustained financing vulnerability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug-delivery platform
Lyra’s focus on a proprietary, localized long‑acting drug-delivery platform for sinonasal tissues creates a durable technical moat in ENT therapeutics. If clinical programs advance, the platform can enable differentiated safety/efficacy profiles and higher barriers to generic competition over the next 2–6 months and beyond.
Read all positive factors
Lyra Therapeutics (LYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$843.07K
Dividend YieldN/A
Average Volume (3M)9.85K
Price to Earnings (P/E)―
Beta (1Y)3.58
Revenue Growth-74.05%
EPS Growth73.08%
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-18.62
Shares Outstanding1,774,882
10 Day Avg. Volume6,177
30 Day Avg. Volume9,854
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.46
Price to Sales (P/S)120.22
P/FCF Ratio-1.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.02
Revenue Forecast (FY)$700.00K
Lyra Therapeutics Business Overview & Revenue Model
Company Description
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique t...
How the Company Makes Money
null...
Lyra Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 398.00K | 1.53M | 1.56M | 1.36M | 285.00K |
| Gross Profit | 398.00K | 1.53M | 1.56M | 1.36M | -29.41M |
| EBITDA | -29.09M | -60.26M | -65.25M | -53.92M | -42.61M |
| Net Income | -28.92M | -93.44M | -62.68M | -55.28M | -43.51M |
Balance Sheet | |||||
| Total Assets | 36.11M | 66.35M | 142.60M | 109.97M | 54.87M |
| Cash, Cash Equivalents and Short-Term Investments | 15.89M | 40.58M | 102.75M | 97.89M | 45.75M |
| Total Debt | 30.26M | 34.38M | 26.88M | 4.18M | 1.45M |
| Total Liabilities | 46.83M | 54.75M | 53.18M | 29.21M | 20.55M |
| Stockholders Equity | -10.72M | 11.59M | 89.42M | 80.75M | 34.32M |
Cash Flow | |||||
| Free Cash Flow | -28.98M | -72.35M | -64.35M | -43.55M | -29.20M |
| Operating Cash Flow | -28.86M | -70.01M | -63.30M | -43.38M | -25.82M |
| Investing Cash Flow | -98.00K | 80.31M | -12.58M | -65.01M | -3.38M |
| Financing Cash Flow | 4.27M | 8.53M | 65.69M | 96.26M | 359.00K |
Lyra Therapeutics Technical Analysis
Negative
0.52
Price Trends
0.61
Negative
0.65
Negative
2.00
Negative
Market Momentum
-0.04
Negative
42.46
Neutral
74.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 0.52 is above the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.61, and below the 200-day MA of 2.00, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.46 is Neutral, neither overbought nor oversold. The STOCH value of 74.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.
Lyra Therapeutics Risk Analysis
Lyra Therapeutics disclosed 24 risk factors in its most recent earnings report. Lyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lyra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $4.83M | -0.09 | -99.39% | ― | ― | 95.40% | |
46 Neutral | $2.00M | 0.04 | -516.87% | ― | ― | 96.81% | |
43 Neutral | $4.32M | -1.36 | -35.38% | ― | ― | 97.67% | |
43 Neutral | $7.67M | -0.25 | -100.90% | ― | 78.64% | 50.70% | |
41 Neutral | $843.07K | -0.03 | 1211.14% | ― | -74.05% | 73.08% | |
39 Underperform | $6.18M | -0.82 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
LYRA
Lyra Therapeutics
0.40
-6.38
-94.10%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.85
-2.71
-48.74%
MBIO
Mustang Bio
0.60
-0.87
-59.46%
BOLT
Bolt Biotherapeutics
3.95
-1.66
-29.59%
RNAZ
TransCode Therapeutics
4.25
-6.86
-61.75%
SLXN
Silexion Therapeutics
1.80
-81.31
-97.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.